Leiomyosarcoma: Difference between revisions

	Leiomyosarcoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Leiomyosarcoma from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Leiomyosarcoma On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Leiomyosarcoma All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Leiomyosarcoma
CDC on Leiomyosarcoma
Leiomyosarcoma in the news
Blogs on Leiomyosarcoma
Directions to Hospitals Treating Leiomyosarcoma
Risk calculators and risk factors for Leiomyosarcoma

VisualWikitext

Revision as of 14:22, 14 June 2018

For patient information click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Leiomyosarcoma from other Diseases:

Epidemiology and Demographics:

Risk Factors:

Natural History, Complications and Prognosis

The majority of patients with leiomyosarcoma remain asymptomatic for decades.
Most leiomyosarcomas are diagnosed incidentally at an advanced stage.
They are invariably aggressive and associated with the poor prognosis.

Prognosis: The prognosis of leiomyosarcoma is poor and it depends on varying factors:

Tumor size
Tumor location
Tumor type/Grade
DNA content
Hormonal receptor status
cellular division and mitotic rate
local and distant extension

Survival Rate of Leiomyosarcoma by staging:

Stage	Percentage
stage 1	60
stage 2	35
stage 3	28
stage 4	15

Diagnosis

Treatment

Leiomyosarcoma treatment consist of multidisciplinary approach and is best carried out at the specialized hospital setting.

Medical Therapy | Surgery | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Related Chapters

Uterine sarcoma

Template:WikiDoc Sources

@@ Line 14: / Line 14: @@
 ==[[Leiomyosarcoma differential diagnosis|Differentiating Leiomyosarcoma from other Diseases]]: ==
 ==[[Leiomyosarcoma epidemiology and demographics|Epidemiology and Demographics]]:==
-==[[Leiomyosarcoma risk factors|Risk Factors]]: <small>Following Risk Fcators found to be associated with the development of the Uterine leiomyosarcoma</small>==
+==[[Leiomyosarcoma risk factors|Risk Factors]]: ==
-* Age: Leiomyosarcoma can be seen at 20 years of age but mean age at diagnosis is 50-60 years old.
-* Race:Black women have a higher incidence of development of the uterine leiomyosarcoma as compared to the white women.<ref name="pmid120503512">Wysowski DK, Honig SF, Beitz J (2002) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12050351 Uterine sarcoma associated with tamoxifen use.] ''N Engl J Med'' 346 (23):1832-3. [http://dx.doi.org/10.1056/NEJM200206063462319 DOI:10.1056/NEJM200206063462319] PMID: [https://pubmed.gov/12050351 12050351]</ref>
-* Long term use of the tamoxifen: Prolonged use of the tamoxifen esp more than five years has been associated with the increased risk of development of leiomyosarcoma.<ref name="pmid11336777">Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG (2001) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11336777 Tamoxifen treatment and gynecologic side effects: a review.] ''Obstet Gynecol'' 97 (5 Pt 2):855-66. PMID: [https://pubmed.gov/11336777 11336777]</ref>
-* History of Pelvic radiations:Pelvic irradiation has been associated with the increased development of the leiomyosarcoma.<ref name="pmid15168177">Fang Z, Matsumoto S, Ae K, Kawaguchi N, Yoshikawa H, Ueda T et al. (2004) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=15168177 Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan.] ''J Orthop Sci'' 9 (3):242-6. [http://dx.doi.org/10.1007/s00776-004-0768-5 DOI:10.1007/s00776-004-0768-5] PMID: [https://pubmed.gov/15168177 15168177]</ref>
-* Certain Hereditary condition like Gardner syndrome, Li-Fraumeni syndrome,Werner syndrome and Neurofibromatosis are associated with the development of leiomyosarcoma.
-* Long term survivors of the Retinoblastoma are at higher risk of developing variety of soft tissue sarcoma.<ref name="pmid19351917">Yu CL, Tucker MA, Abramson DH, Furukawa K, Seddon JM, Stovall M et al. (2009) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19351917 Cause-specific mortality in long-term survivors of retinoblastoma.] ''J Natl Cancer Inst'' 101 (8):581-91. [http://dx.doi.org/10.1093/jnci/djp046 DOI:10.1093/jnci/djp046] PMID: [https://pubmed.gov/19351917 19351917]</ref>
 ==[[Leiomyosarcoma natural history|Natural History, Complications and Prognosis]]==
 * The majority of patients with leiomyosarcoma remain asymptomatic for decades.